Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belimumab and Rituximab Sequential Therapy in SLE
NCT03312907Phase 3Completed
- Sponsor
- GSK
- Start
- Mar 2018
- Primary completion
- May 2020
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 3 trial of rituximab in systemic lupus erythematosus (SLE), sponsored by GSK. Started Mar 2018; status: completed.
02
Drugs
rituximab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT03312907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03312907.